Theriva Biologics, Inc. (TOVX) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K covers events occurring on August 29, 2025, specifically the Company's 2025 Annual Meeting of Stockholders. Theriva Biologics, Inc. is a Nevada corporation with its principal executive offices in Rockville, Maryland, and its common stock trades on the NYSE American under the symbol "TOVX."
Key Financial Metrics
This filing is a corporate governance report and does not contain financial performance data. There are no disclosures regarding revenue, profit, cash flow, margins, debt, or liquidity in this document.
Material Changes and Corporate Actions
The filing details the results of five proposals voted upon by stockholders at the Annual Meeting:
- Stock Incentive Plan Amendment (Proposal 3): Stockholders approved an amendment to the 2020 Stock Incentive Plan, increasing the authorized share pool from 2,500,000 to 4,500,000 shares of common stock.
- Election of Directors (Proposal 1): Four directors were elected: Jeffrey J. Kraws, Steven A. Shallcross, John Monahan, and Jeffrey Wolf. All received significant "For" votes, though approximately 2.2 million broker non-votes were recorded for each candidate.
- Auditor Ratification (Proposal 2): Stockholders ratified the appointment of BDO USA, P.C. as the independent registered public accounting firm for the year ending December 31, 2025.
- Executive Compensation (Proposal 4): Stockholders approved, on an advisory basis, the compensation of named executive officers.
- Compensation Vote Frequency (Proposal 5): Stockholders approved holding future advisory votes on executive compensation every three years.
Guidance, Outlook, and Risks
The filing contains no management commentary on business outlook, financial guidance, or specific risk factors. The document references the Definitive Proxy Statement (filed July 9, 2025) for detailed descriptions of the proposals and the amended Stock Incentive Plan.
Key Facts for Investor Verification
- Verify the impact of the increased equity pool (4.5 million shares) on potential future dilution.
- Review the Definitive Proxy Statement (Schedule 14A) for the full text of Amendment No. 3 to the 2020 Stock Incentive Plan.
- Note the significant number of broker non-votes (2,212,112) in the director elections, indicating shares held in street name where brokers lacked discretionary voting power.
- Confirm the three-year cycle for future executive compensation advisory votes.